Sichuan Kelun Pharmaceutical Co., Ltd. Class A
002422
주식 순위
#2010
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and... Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
주가
$6.40
시가총액
$10.19B
변동 (1일)
-0.77%
변동 (1년)
27.14%
국가
CN
거래 Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)
카테고리
Healthcare
Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)의 수익
Jun 2026 기준 수익 TTM: $380.26M
Sichuan Kelun Pharmaceutical Co., Ltd. Class A의 최신 재무 보고서에 따르면 회사의 현재 수익은 $380.26M입니다. 2024년에 회사는 $587.11M의 수익을 올렸으며 이는 2023년의 수익 $505.81M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Sichuan Kelun Pharmaceutical Co., Ltd. Class A의 수익 기록 (2007 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $380.26M | 10.67% |
| 2025 | $343.58M | -41.48% |
| 2024 | $587.11M | 16.07% |
| 2023 | $505.81M | 68.72% |
| 2022 | $299.79M | 61.80% |
| 2021 | $185.28M | 26.74% |
| 2020 | $146.19M | -18.97% |
| 2019 | $180.42M | -6.93% |
| 2018 | $193.85M | 10.51% |
| 2017 | $175.41M | 69.99% |
| 2016 | $103.19M | -1.58% |
| 2015 | $104.84M | -43.47% |
| 2014 | $185.46M | -12.29% |
| 2013 | $211.43M | 3.94% |
| 2012 | $203.43M | 14.70% |
| 2011 | $177.35M | 51.03% |
| 2010 | $117.43M | 53.61% |
| 2009 | $76.45M | 48.40% |
| 2008 | $51.51M | 46.84% |
| 2007 | $35.08M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | 1,287.20% |
US
|
|
| $-3.09B | -911.82% |
US
|
|
| $-4.02B | -1,156.18% |
AU
|
|
| $3.01B | 690.44% |
BE
|
|
| $1.95B | 412.98% |
NL
|
